Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philipp Mandel

Showing results (71-80 of 220) with videos related to

Pageof 22
Sort By:
European Urology Oncology|September 1, 2024
Prostate-specific Antigen Nadir and Cancer-Control Outcomes in Real-world Apalutamide-treated Metastatic Hormone-Sensitive Prostate Cancer Patients: A Single-Center AnalysisMike Wenzel, Cristiana Cano Garcia, Clara Humke, et al.
Urologic Oncology|July 30, 2021
The impact of time to prostate specific antigen nadir on biochemical recurrence and mortality rates after radiation therapy for localized prostate cancerMike Wenzel, Charles Dariane, Fred Saad, et al.
Cancers|January 21, 2023
Baseline [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT before [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy: Value of PSMA-Uptake Thresholds in Predicting Targetable LesionsDaniel Groener, Sina Schneider, Justus Baumgarten, et al.
Frontiers in Surgery|October 18, 2019
MRI-Fusion Targeted vs. Systematic Prostate Biopsy-How Does the Biopsy Technique Affect Gleason Grade Concordance and Upgrading After Radical Prostatectomy?Jessica Rührup, Felix Preisser, Lena Theißen, et al.
BJU International|February 26, 2015
Salvage radical prostatectomy for recurrent prostate cancer: verification of European Association of Urology guideline criteriaPhilipp Mandel, Thomas Steuber, Sascha Ahyai, et al.
Urologic Oncology|October 24, 2020
Oncological outcomes of pathologically organ-confined, lymph node-positive prostate cancer after radical prostatectomyLara Franziska Stolzenbach, Sophie Knipper, Philipp Mandel, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 13, 2025
Lutetium-177 PSMA radioligand therapy in taxan-naive first- and second-line metastatic castration resistant prostate cancer after first-line ARPI therapyMike Wenzel, Benedikt Hoeh, Carolin Siech, et al.
European Urology Focus|July 13, 2019
Performance of Combined Magnetic Resonance Imaging/Ultrasound Fusion-guided and Systematic Biopsy of the Prostate in Biopsy-naïve Patients and Patients with Prior BiopsiesFelix Preisser, Lena Theissen, Mike Wenzel, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 7, 2025
Cancer-control outcomes of Radium- 223-pretreated lutetium- 177-PSMA Radioligand vs. Radium- 223-naïve mCRPC patientsMike Wenzel, Lena Theissen, Daniel Groener, et al.
European Urology Focus|December 6, 2024
Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: An Updated Network Meta-analysis Including ARANOTE DataBenedikt Hoeh, Mike Wenzel, Zhe Tian, et al.
Pageof 22

Showing results (71-80 of 220) with videos related to

Sort By:
Pageof 22
European Urology Oncology|September 1, 2024
Prostate-specific Antigen Nadir and Cancer-Control Outcomes in Real-world Apalutamide-treated Metastatic Hormone-Sensitive Prostate Cancer Patients: A Single-Center AnalysisMike Wenzel, Cristiana Cano Garcia, Clara Humke, et al.
Urologic Oncology|July 30, 2021
The impact of time to prostate specific antigen nadir on biochemical recurrence and mortality rates after radiation therapy for localized prostate cancerMike Wenzel, Charles Dariane, Fred Saad, et al.
Cancers|January 21, 2023
Baseline [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT before [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy: Value of PSMA-Uptake Thresholds in Predicting Targetable LesionsDaniel Groener, Sina Schneider, Justus Baumgarten, et al.
Frontiers in Surgery|October 18, 2019
MRI-Fusion Targeted vs. Systematic Prostate Biopsy-How Does the Biopsy Technique Affect Gleason Grade Concordance and Upgrading After Radical Prostatectomy?Jessica Rührup, Felix Preisser, Lena Theißen, et al.
BJU International|February 26, 2015
Salvage radical prostatectomy for recurrent prostate cancer: verification of European Association of Urology guideline criteriaPhilipp Mandel, Thomas Steuber, Sascha Ahyai, et al.
Urologic Oncology|October 24, 2020
Oncological outcomes of pathologically organ-confined, lymph node-positive prostate cancer after radical prostatectomyLara Franziska Stolzenbach, Sophie Knipper, Philipp Mandel, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 13, 2025
Lutetium-177 PSMA radioligand therapy in taxan-naive first- and second-line metastatic castration resistant prostate cancer after first-line ARPI therapyMike Wenzel, Benedikt Hoeh, Carolin Siech, et al.
European Urology Focus|July 13, 2019
Performance of Combined Magnetic Resonance Imaging/Ultrasound Fusion-guided and Systematic Biopsy of the Prostate in Biopsy-naïve Patients and Patients with Prior BiopsiesFelix Preisser, Lena Theissen, Mike Wenzel, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 7, 2025
Cancer-control outcomes of Radium- 223-pretreated lutetium- 177-PSMA Radioligand vs. Radium- 223-naïve mCRPC patientsMike Wenzel, Lena Theissen, Daniel Groener, et al.
European Urology Focus|December 6, 2024
Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: An Updated Network Meta-analysis Including ARANOTE DataBenedikt Hoeh, Mike Wenzel, Zhe Tian, et al.
Pageof 22